Author Correction: Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress
Xihui Liu, Suryavathi Viswanadhapalli, Shourya Kumar, Tae-Kyung Lee, Andrew Moore, Shihong Ma, Liping Chen, Michael Hsieh, Mengxing Li, Gangadhara R. Sareddy, Karla Parra, Eliot B. Blatt, Tanner C. Reese, Yuting Zhao, Annabel Chang, Hui Yan, Zhenming Xu, Uday P. Pratap
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsEndoplasmic Reticulum Stress and Disease · PARP inhibition in cancer therapy · Metabolism and Genetic Disorders
Correction to: Nature Cancer 10.1038/s43018-022-00389-8, published online 2 June 2022
In the version of this article initially published, in the legend to Extended Data Fig. 2a, the dose of ERX-41 was reported as 10 mg/kg/day for both BALB/c and nude mice, but the BALB/c mice were in fact administered 20 mg/kg/day. The correct figure legend for Extended Data Fig. 2a is “Nude mice with MDA-MB-231 xenograft tumors were treated with either a vehicle or ERX-41 (10 mg/kg/day) for a duration of 52 days. Similarly, BALB/c mice with D2A1 xenograft tumors received a treatment of 20 mg/kg/day for 23 days. Following these treatments, histologic architecture in various organs of both the nude mice and BALB/c mice was assessed using H&E staining (a).” This has been corrected in the HTML and PDF versions of the article.